FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032352566> ?p ?o ?g. }

• W3032352566 endingPage "271" @default.
• W3032352566 startingPage "264" @default.
• W3032352566 abstract "Background: One of the most widely used risk stratification systems for estimating individual patients' risk of persistent or recurrent differentiated thyroid cancer (DTC) is the American Thyroid Association (ATA) guidelines. The 2015 ATA version, which has increased the number of patients considered at low or intermediate risk, has been validated in several retrospective, single-center studies. The aims of this study were to evaluate the real-world performance of the 2015 ATA risk stratification system in predicting the response to treatment 12 months after the initial treatment and to determine the extent to which this performance is affected by the treatment center in which it is used. Methods: A prospective cohort of DTC patients collected by the Italian Thyroid Cancer Observatory web-based database was analyzed. We reviewed all records present in the database and selected consecutive cases that satisfied inclusion criteria: (i) histological diagnosis of DTC, with the exclusion of noninvasive follicular thyroid neoplasm with papillary-like nuclear features; (ii) complete data of the initial treatment and pathological features; and (iii) results of 1-year follow-up visit (6–18 months after the initial treatment), including all data needed to classify the estimated response to treatment. Results: The final cohort was composed of 2071 patients from 40 centers. The ATA risk of persistent/recurrent disease was classified as low in 1109 patients (53.6%), intermediate in 796 (38.4%), and high in 166 (8.0%). Structural incomplete responses were documented in only 86 (4.2%) patients: 1.5% in the low-risk, 5.7% in the intermediate-risk, and 14.5% in the high-risk group. The baseline ATA risk class proved to be a significant predictor of structural persistent disease, both for intermediate-risk (odds ratio [OR] 4.67; 95% confidence interval [CI] 2.59–8.43) and high-risk groups (OR 16.48; CI 7.87–34.5). Individual center did not significantly influence the prediction of the 1-year disease status. Conclusions: The ATA risk stratification system is a reliable predictor of short-term outcomes in patients with DTC in real-world clinical settings characterized by center heterogeneity in terms of size, location, level of care, local management strategies, and resource availability." @default.
• W3032352566 created "2020-06-05" @default.
• W3032352566 creator A5000989087 @default.
• W3032352566 creator A5007046109 @default.
• W3032352566 creator A5007190520 @default.
• W3032352566 creator A5009389934 @default.
• W3032352566 creator A5011627191 @default.
• W3032352566 creator A5013226943 @default.
• W3032352566 creator A5016309956 @default.
• W3032352566 creator A5017104680 @default.
• W3032352566 creator A5017766225 @default.
• W3032352566 creator A5018051509 @default.
• W3032352566 creator A5021361429 @default.
• W3032352566 creator A5026090512 @default.
• W3032352566 creator A5026131593 @default.
• W3032352566 creator A5027356547 @default.
• W3032352566 creator A5027823950 @default.
• W3032352566 creator A5029296923 @default.
• W3032352566 creator A5034380582 @default.
• W3032352566 creator A5038828476 @default.
• W3032352566 creator A5043454137 @default.
• W3032352566 creator A5044114640 @default.
• W3032352566 creator A5046084794 @default.
• W3032352566 creator A5052497561 @default.
• W3032352566 creator A5052716690 @default.
• W3032352566 creator A5055086811 @default.
• W3032352566 creator A5055208154 @default.
• W3032352566 creator A5055505106 @default.
• W3032352566 creator A5055846733 @default.
• W3032352566 creator A5062841107 @default.
• W3032352566 creator A5064170949 @default.
• W3032352566 creator A5064225775 @default.
• W3032352566 creator A5067937169 @default.
• W3032352566 creator A5068090112 @default.
• W3032352566 creator A5069110450 @default.
• W3032352566 creator A5070792544 @default.
• W3032352566 creator A5074195972 @default.
• W3032352566 creator A5074939405 @default.
• W3032352566 creator A5075362203 @default.
• W3032352566 creator A5078350860 @default.
• W3032352566 creator A5079074403 @default.
• W3032352566 creator A5080632239 @default.
• W3032352566 creator A5081971753 @default.
• W3032352566 creator A5085467485 @default.
• W3032352566 creator A5085931728 @default.
• W3032352566 date "2021-02-01" @default.
• W3032352566 modified "2023-10-17" @default.
• W3032352566 title "Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients" @default.
• W3032352566 cites W1951724000 @default.
• W3032352566 cites W1999758442 @default.
• W3032352566 cites W2006758787 @default.
• W3032352566 cites W2034542445 @default.
• W3032352566 cites W2053272999 @default.
• W3032352566 cites W2110829017 @default.
• W3032352566 cites W2116542352 @default.
• W3032352566 cites W2132296761 @default.
• W3032352566 cites W2138719858 @default.
• W3032352566 cites W2145150141 @default.
• W3032352566 cites W2262362062 @default.
• W3032352566 cites W2323823264 @default.
• W3032352566 cites W2338183204 @default.
• W3032352566 cites W2405084038 @default.
• W3032352566 cites W2467616276 @default.
• W3032352566 cites W2533416322 @default.
• W3032352566 cites W2551013377 @default.
• W3032352566 cites W2559596934 @default.
• W3032352566 cites W2762830229 @default.
• W3032352566 cites W2765984386 @default.
• W3032352566 cites W2774569033 @default.
• W3032352566 cites W2784174721 @default.
• W3032352566 cites W2807817855 @default.
• W3032352566 cites W2887116045 @default.
• W3032352566 cites W2888750531 @default.
• W3032352566 cites W2921866665 @default.
• W3032352566 cites W2947768503 @default.
• W3032352566 cites W2965599700 @default.
• W3032352566 cites W2975387808 @default.
• W3032352566 doi "https://doi.org/10.1089/thy.2020.0272" @default.
• W3032352566 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32475305" @default.
• W3032352566 hasPublicationYear "2021" @default.
• W3032352566 type Work @default.
• W3032352566 sameAs 3032352566 @default.
• W3032352566 citedByCount "34" @default.
• W3032352566 countsByYear W30323525662020 @default.
• W3032352566 countsByYear W30323525662021 @default.
• W3032352566 countsByYear W30323525662022 @default.
• W3032352566 countsByYear W30323525662023 @default.
• W3032352566 crossrefType "journal-article" @default.
• W3032352566 hasAuthorship W3032352566A5000989087 @default.
• W3032352566 hasAuthorship W3032352566A5007046109 @default.
• W3032352566 hasAuthorship W3032352566A5007190520 @default.
• W3032352566 hasAuthorship W3032352566A5009389934 @default.
• W3032352566 hasAuthorship W3032352566A5011627191 @default.
• W3032352566 hasAuthorship W3032352566A5013226943 @default.
• W3032352566 hasAuthorship W3032352566A5016309956 @default.
• W3032352566 hasAuthorship W3032352566A5017104680 @default.
• W3032352566 hasAuthorship W3032352566A5017766225 @default.
• W3032352566 hasAuthorship W3032352566A5018051509 @default.

• next